Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
The Science Business
Org Prep Daily
Kilomentor
On Pharma
Kinase Pro
A New Merck, Reviewed
Pharma Conduct
One in Ten Thousand
Periodic Tabloid
All Things Metathesis
C&E News Blog
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Chirality
Mad Chemist Chick
BBSRC/Douglas Kell
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
Chemical Crystallinity
ChemSpider Blog
Pharmagossip
Med-Chemist
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
Great Molecular Crapshoot
No Name No Slogan
Practical Fragments
SimBioSys
Culture of Chemistry
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Zusammen
My Chemical Journey
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
Curly Arrow
ChemCafe
Fetz the Chemist
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Living the Scientific Life
Humans in Science
Speculist
Science, Shrimp and Grits
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« But These Reagents, Where Are They? | Main | K. C. Nicolaou, Call Your Office »

November 23, 2009

Ozonides As Drugs: What Will They Think of Next?

Email This Entry

Posted by Derek

You know, I often think that I have too narrow a view of what kinds of structures can go into drug molecules. (That may come as worrisome statement for some past and present colleagues of mine, who feel that my tolerances are already set a bit too wide!) But I do have limits; there are some structures that I just wouldn't make on purpose, and which I wouldn't submit for testing even if I made them by accident.

Surely ozonides fall into this category. But when I put the "Things I Won't Work With" stamp on them, at least as far as making them on scale and actually isolating them, some readers pointed out that people were investigating them for antimalarial activity. And here we are, with a new paper in J. Med. Chem. on their activity and properties.

Arterolane is the lead compound, which is in Phase III trials as a combination therapy. And it has to be one of the funkier structures ever to make it as far as Phase III, for sure, with both an ozonide and an adamantane in it. Those two, in fact, sort of cancel each other out - the steric hindrance of the adamantane is surely one of the things that makes the ozonide decide not to explode, as its smaller and more footloose chemical relatives would. You get blood levels of the stuff after oral dosing, a useful (although not especially long) half-life, and no show-stopping toxicity.
arterolane.jpg
Endoperoxides are already known as antimalarials, thanks to the natural product arteminisin, which has led to two synthetic derivatives used as antimalarials. So the step to ozonides was, structurally, a small one, but must have been rather larger psychologically. And that's definitely not something to discount. I probably wouldn't have made compounds of this sort, and it's unnerving (even to me) that arterolane has gone further into the clinic than anything I've ever made. I have to congratulate the people who had the imagination to pursue these things.

Comments (15) + TrackBacks (0) | Category: Drug Development | Infectious Diseases | Odd Elements in Drugs


COMMENTS

1. You're Pfizered on November 23, 2009 10:14 AM writes...

But is it Rule of Five compliant?

;)

Permalink to Comment

2. Anonymous on November 23, 2009 10:37 AM writes...

Pfizered,

Stick ye olde morpholine somewhere on there and it'll be fine.

Permalink to Comment

3. petros on November 23, 2009 10:47 AM writes...

And its stability in tropical climes is?

Any antimalarial has to be very chemically stable becuase of the extreme conditions it is likley to be stored in

Permalink to Comment

4. You're Pfizered on November 23, 2009 11:08 AM writes...

If it's in Phase III, all kinds of stress-tests for stability have been done by the corresponding development areas, giving a read on what conditions the drug product needs to be stored under and what the shelf-life under those conditions would be.

Had there been any type of severe thermal or chemical instability, it should have been discovered by now and its development probably would have ended.

Permalink to Comment

5. Little Miss Process on November 23, 2009 11:47 AM writes...

Under the right structural circumstances, ozonides can be quite stable. I made one during my postdoc, and it didn't go "bang", although it did rapidly rearrange to the product I wanted with a little acid. As Pfizered says, the process safety guys will have tested it for thermal stability, and at this phase, the formulation groups will have acquired degradation data too. Well, I say "will have". I don't work for the company in question, so perhaps I should say "should have".

Permalink to Comment

6. Petros on November 23, 2009 12:11 PM writes...

This link gives some details of the studies done

http://www.mmv.org/IMG/pdf/02_RBX11160_-_Ranbaxy_-_MMV_conference_Mumbai_IRS.pdf

Permalink to Comment

7. Sili on November 23, 2009 3:21 PM writes...

Wouldn't a qualified guess be that they were shooting for a peroxide, and this happened to pop out instead?

Permalink to Comment

8. Igor on November 23, 2009 6:14 PM writes...

With many successful drugs out there that look "ugly", e.g. metformin and taxol, from a typical small molecule perspective, this one really doesn't look all that unusual. After having some difficulty in decomposing some hindered ozonides in the past, the stability of this one does not surprise me.

As a generalization, I do think that we as med chemists need to try to step out of the heteroaryl-core-attached-to-some-lipophilic-groups-and-a-solubilizing-group mentality; otherwise, we might as well move overseas and just make analogs.

I hope the ozonide works and actually is a benefit to society, regardless of its perceived structural liabilities.

Permalink to Comment

9. A Nonny Mouse on November 24, 2009 12:59 PM writes...

I remember being shown a paper by a colleague in the mid-1980s. He had been sent the paper to review which was the X-ray structure of a natural product with anti-malarial properties. He showed it to me and I said "NO WAY!". We decided that they had definitely done something wrong and got carbons and oxygens mixed up as the structure could not possibly exist. Yes, it was Artemesin...........

Permalink to Comment

10. Sili on November 25, 2009 11:41 AM writes...

I take it it wasn't an Ortep drawing, A Nonny?

More than once have I shook my head at published work (even by people I know), where they've obviously swapped around Nitrogen and Carbon in an uncoördinated pyridyl ring.

Permalink to Comment

11. A Nonny Mouse on November 27, 2009 6:36 AM writes...

Yes, it was an ORTEP, but they were Chinese.......

Permalink to Comment

12. Sili on November 27, 2009 1:11 PM writes...

I feel bad for laughing at that ...

Permalink to Comment

13. Artem on November 28, 2009 9:04 PM writes...

Given the fact that nitroglycerin is a drug since eighteen-freakin-seventy - this one doesn't shock me at all.

I've had my share of failed attempts to persuade the wise and powerful chemists to make small molecules that are 'obviously wrong for numerous/obvious reasons I am too busy to go into' - only to watch those very same things appear in a more cavalier company's patent literature years later. To me the lesson of the story is - get out of the box or be buried in it.

Permalink to Comment

14. Design Monkey on November 30, 2009 11:25 AM writes...

Not about ozonides, but another odd element - actually there is a silicone containing drug, that is being sold for human use and with (quite) a bit funky structure even - 1-(chloromethyl)silatrane, mival, as a baldness treatment agent in Russia. Most papers and information about it are available in russian only.

Permalink to Comment

15. petros on December 1, 2009 3:44 PM writes...

Another ugly drug, containg selenium, is ebselen
http://en.wikipedia.org/wiki/Ebselen.

This was filed, but not approved, in Japan.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A GSK/Sirtris Wrap-Up
Hope Darn Well Springs Eternal
Bad News at Exelixis
Not Gonna Make That One
Merck/Schering-Plough People?
Friday Book Recommendation
Twelve and One Half Per Cent
Your Own Personal Bacteria